Navigation Links
IP-K extends research deal with Novartis Institute for Tropical Diseases
Date:12/2/2010

Dec. 03, 2010, Seoul, S. Korea Institut Pasteur Korea (IP-K) has signed an agreements to continue to mine the chemical compound collection of Novartis Institute for Tropical Diseases (NITD) of Singapore for new drug candidates.

IP-K's PhenomicScreen is a high-throughput, high-content visual screening platform that is ideally suited to identifying lead compounds. Over the past year, PhenomicScreen has been used to search for promising drugs within NITD's chemical compound collection. That deal has now been extended by two years to allow a further exploration of their chemical library.

Dr. Pablo Bifani, Project Team Head at NITD, welcomed his institute's new contract, noting that "The scientific approach we are taking with IP-K is greatly facilitating the selection of candidate compounds for further drug development."

IP-K's Dr. Jonathan Cechetto describes the advantages of PhenomicScreen as being that "The process selects novel targets, and only those which are functionally significant in the disease process". Dr. Priscille Brodin of IP-K adds that "The phenotypic approach does not rely on a predefined target, but rather simultaneously selects both chemical compounds and an unknown cellular target solely by the clearly discernible effect on the disease model".

Center Director of Core Technologies of Institut Pasteur Korea Dr. Veronica Soloveva said that "We are proud to be working with NITD in the fight against infectious diseases". Soloveva is satisfied that the agreement is a vindication of the institute's innovative approach to drug discovery. "Our PhenomicScreen technology is proven to increase the accuracy and speed of drug discovery," she says.


'/>"/>

Contact: Jean Kim
babunn@ip-korea.org
82-318-018-8041
Institut Pasteur Korea
Source:Eurekalert

Page: 1

Related biology news :

1. GenWay Biotech extends the You Test You program overseas
2. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
3. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
4. $5.1 million Army-Md. alliance speeds university research to market
5. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
6. Researchers describe first functioning lipidome of mouse macrophage
7. U of M researcher helps unlock 30 new genes responsible for early onset puberty
8. Stroke research takes 2 steps forward
9. Researchers find link between sugar, diabetes and aggression
10. Arjun Deb awarded Louis N. and Arnold M. Katz Basic Science Research Prize
11. Snakes on a rope: Researchers take a unique look at the climbing abilities of boa constrictors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), ... Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will ... “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment industries. ...
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma A/S ... innovative TransCon technology to address significant unmet medical ... for the full year ended December 31, 2016. ... for our company as we broadened our pipeline ... integrated rare disease company with an initial focus ...
(Date:3/22/2017)... , March 22, 2017 Oramed ... ( www.oramed.com ), a ... oral drug delivery systems, announced today that Dr. ... will deliver a presentation titled, "Oral Insulin for ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com ... ... cancer conditions are being pressured as of late due to ... cancer pain management has a dramatic impact on patient,s quality ... and development activities for identifying new forms of opioid formulations ...
Breaking Biology Technology: